全文获取类型
收费全文 | 1165篇 |
免费 | 69篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 42篇 |
妇产科学 | 17篇 |
基础医学 | 142篇 |
口腔科学 | 29篇 |
临床医学 | 111篇 |
内科学 | 275篇 |
皮肤病学 | 16篇 |
神经病学 | 137篇 |
特种医学 | 16篇 |
外科学 | 169篇 |
综合类 | 1篇 |
预防医学 | 74篇 |
眼科学 | 5篇 |
药学 | 76篇 |
中国医学 | 2篇 |
肿瘤学 | 122篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 27篇 |
2020年 | 17篇 |
2019年 | 24篇 |
2018年 | 20篇 |
2017年 | 26篇 |
2016年 | 16篇 |
2015年 | 23篇 |
2014年 | 37篇 |
2013年 | 59篇 |
2012年 | 88篇 |
2011年 | 88篇 |
2010年 | 38篇 |
2009年 | 44篇 |
2008年 | 76篇 |
2007年 | 75篇 |
2006年 | 88篇 |
2005年 | 68篇 |
2004年 | 81篇 |
2003年 | 60篇 |
2002年 | 70篇 |
2001年 | 15篇 |
2000年 | 11篇 |
1999年 | 12篇 |
1998年 | 12篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 12篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 11篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 3篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1969年 | 3篇 |
1968年 | 2篇 |
1966年 | 1篇 |
1939年 | 1篇 |
1937年 | 2篇 |
排序方式: 共有1243条查询结果,搜索用时 640 毫秒
71.
Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. 总被引:4,自引:0,他引:4
Filippo Spreafico Maura Massimino Roberto Luksch Michela Casanova Graziella S Cefalo Paola Collini Andrea Ferrari Daniela Polastri Monica Terenziani Marco Gasparini Franca Fossati-Bellani 《Journal of clinical oncology》2002,20(12):2783-2788
PURPOSE: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified. PATIENTS AND METHODS: From May 1987 to February 2001, 60 children, median age 9 years (range, 2.1 to 17 years), with advanced BL were enrolled onto two sequential institutional studies. From 1987 to 1992, 30 patients were stratified according to the absence (regimen IA, n = 19) or presence (regimen IB, n = 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion. Regimen IB was intensified by adding etoposide and HD ifosfamide and escalating MTX doses. Since 1992, regardless of BM or CNS status, 30 patients have been placed on regimen II, which is identical to IB but without ifosfamide. The scheduled duration of regimen II was 45 days. RESULTS: EFS and disease-free survival at 5 years are 81% +/- 5% and 87% +/- 5%, respectively, for 59 assessable patients (73% +/- 8% and 85% +/- 7% for regimen IA + IB, 89% +/- 6%, EFS and disease-free survival, for regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications. CONCLUSION: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration. 相似文献
72.
Giuliana Cassinelli Cinzia Lanzi Rosanna Supino Graziella Pratesi Valentina Zuco Diletta Laccabue Giuditta Cuccuru Ezio Bombardelli Franco Zunino 《Clinical cancer research》2002,8(8):2647-2654
Taxane-based therapies appear to have a significant efficacy in clinical trials on hormone-refractory prostate carcinoma. In the present study, we investigated the cellular response of androgen-independent prostate carcinoma cell lines to the novel taxane IDN 5109 (BAY 59-8862) and evaluated its antitumor activity. In previous preclinical studies, this new paclitaxel (PTX) analogue was characterized by high tolerability and antitumor efficacy, ability to overcome multidrug resistance, and activity by oral administration. Upon treatment, DU145 and PC3 prostate carcinoma cell lines underwent a transient mitotic arrest. This was followed by G1 arrest and rapid occurrence of apoptosis in DU145 cells, whereas in PC3 cells, which are defective for the postmitotic checkpoint, a slow cell death was preceded by DNA endoreduplication. At the biochemical level, such events were associated with tubulin polymerization, activation of the mitosis-promoting factor, and phosphorylation of Bcl-X(L)/Bcl-2/Raf-1. In addition, IDN 5109 shared with PTX the ability to down-regulate the expression of the two potent angiogenic factors vascular endothelial growth factor and basic fibroblast growth factor. These findings indicated that IDN 5109 affected the same pathways involved in the cellular response to PTX and suggested that an antiangiogenic effect mediated by inhibition of paracrine stimulation of endothelial cells might contribute to the antitumor effect of both drugs. In in vivo experiments, the new taxane displayed a superior and more persistent effect compared with PTX against DU145 tumor xenografts. Such an effect was associated with pronounced reduction of the tumor microvessel density, superior to that achieved by PTX. These results support a potential therapeutic advantage of IDN 5109 over PTX against hormone-refractory prostate carcinoma. 相似文献
73.
74.
Spreafico F Massimino M Gandola L Cefalo G Mazza E Landonio G Pignoli E Poggi G Terenziani M Pedrazzoli P Siena S Fossati-Bellani F 《European journal of cancer (Oxford, England : 1990)》2005,41(9):1304-1310
We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols. Between 1987 and 2003, patients 18 years old were given adjuvant chemotherapy consisting of one of two 'paediatric' regimens (depending on the time of presentation) and craniospinal local-boost radiotherapy: regimen A (n = 12), vincristine (VCR), intrathecal and/or intravenous methotrexate and conventional radiotherapy; or regimen B (n = 11) sequencing intensive doses of multiple agents followed by hyperfractionated accelerated radiotherapy (HART). A VCR-lomustine-based maintenance followed both regimens. Three additional patients received a tailored treatment due to their impaired neurological status after surgery. The median age at diagnosis was 26 years (range 18-41 years). With a median follow-up of 46 months, 5-year disease-free and overall survival rates were 65+/-11% and 73+/-10%, respectively, for the series as a whole. All patients who received regimen B (5 of whom had metastatic Chang M2-M3 disease) are alive with no evidence of disease at 39 months. Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors. 相似文献
75.
De Cesare M Perego P Righetti SC Pratesi G Carenini N Rivoltini L Zupi G Del Bufalo D Balsari A Zunino F 《European journal of cancer (Oxford, England : 1990)》2005,41(8):1213-1222
The anti-apoptotic protein Bcl-2 has been implicated in the intrinsic resistance of melanoma to chemotherapy. The aim of this study was to investigate the effects of anti-Bcl-2 oligonucleotide oblimersen on the antitumour activity of gimatecan, a novel lipophilic camptothecin currently undergoing clinical phase II studies. Results showed a reduced sensitivity of melanoma cells to gimatecan following Bcl-2 transfection and inversely, increased cell sensitivity to gimatecan in combination with oblimersen. In in vivo studies performed in two melanoma xenografts expressing different Bcl-2 levels, the antitumour activity of oblimersen itself was modest, but the combination with gimatecan produced a significant therapeutic advantage. The combination therapy inhibited tumour growth and delayed regrowth of the two tumours tested. The enhancement of antitumour activity was observed at doses that were tolerated well. The effects of oblimersen on antitumour activity and toxicity of gimatecan were dose-dependent. The capability of oblimersen to improve the efficacy of gimatecan supports the therapeutic potential of the drug combination in the treatment of human melanoma. 相似文献
76.
Carbone A Rodeck U Mauri FA Sozzi M Gaspari F Smirne C Prati A Addeo A Novarino A Robecchi A Bertetto O Emanuelli G Bellone G 《Cancer biology & therapy》2005,4(2):231-241
Recently we observed that pancreatic carcinoma cell lines constitutively express Interleukin-18 (IL-18). Bioactive IL-18 induces Interferon (IFN)-gamma production, Fas Ligand (FasL) expression, and inhibits angiogenesis, raising the issue of anti-tumor effects of a tumor-derived cytokine and motivating a more detailed analysis of IL-18 production in pancreatic carcinoma cells. This analysis included the study of effects of chemotherapeutic drugs (5-fluorouracil [5-FU], gemcitabine, cisplatin) commonly used in the treatment of pancreatic cancer patients on IL-18 production and processing. IL-18 expression and post-translational processing were determined using RT-PCR, immunoblot and ELISA in pancreatic carcinoma cell lines and in tumor tissue and serum samples from pancreatic carcinoma patients in the presence and absence of chemotherapeutic drugs. We describe expression of IL-18 in pancreatic carcinoma cells and tissues associated with significantly elevated IL-18 levels in patients sera. Specifically, Capan-2 pancreatic tumor cells produced and secreted precursor IL-18 with no apparent biological activity. However, the chemotherapeutic agent 5-FU, by inducing Caspase-1 and Caspase-3 activation, induced secretion of proteolytically processed mature and degraded IL-18 species, respectively, in Capan-2 cells. Conditioned medium from 5-FU-treated but not control Capan-2 cells induced IFN-gamma production by activated T cells in an IL-18-dependent manner. Furthermore, adjuvant polychemotherapy including 5-FU significantly increased serum levels of mature, bioactive IL-18 in pancreatic carcinoma patients. Treatment of pancreatic cancer cells with 5-FU induced Caspase-dependent processing of pro-IL18 leading to the secretion of biologically active IL-18. These findings delineate a novel mechanism by which chemotherapeutic agents may modulate local anti-tumor cell-mediated immune responses. 相似文献
77.
Pocar M Moneta A Donatelli F 《Archives of surgery (Chicago, Ill. : 1960)》2005,140(10):1009-10; author reply 1010
78.
79.
Ambrosino G Varotto S Strom SC Guariso G Franchin E Miotto D Caenazzo L Basso S Carraro P Valente ML D'Amico D Zancan L D'Antiga L 《Cell transplantation》2005,14(2-3):151-157
Crigler-Najjar syndrome type 1 (CN1) is an inherited disorder characterized by the absence of hepatic uridine diphosphoglucuronate glucuronosyltransferase (UDPGT), the enzyme responsible for the conjugation and excretion of bilirubin. We performed allogenic hepatocyte transplantation (AHT) in a child with CN1, aiming to improve bilirubin glucuronidation in this condition. A 9-year-old boy with CN1 was prepared with plasmapheresis and immunosuppression with prednisolone and tacrolimus. When a graft was made available, 7.5 x 10(9) hepatocytes were isolated and infused into the portal vein percutaneously. After 2 weeks phenobarbitone was added to promote the enzymatic activity of UDPGT of the transplanted hepatocytes. Nocturnal phototherapy was continued throughout the studied period. Total bilirubin was considered a reliable marker of allogenic cell function. There was no significant variation of vital signs nor complications during the infusion. Mean +/- SD bilirubin level was 530 +/- 38 micromol/L before and 359 +/- 46 micromol/L after AHT (t-test, p < 0.001). However, the introduction of phenobarbitone was followed by a drop of tacrolimus level with increase of alanine aminotransferase (ALT) and increase of bilirubin. After standard treatment of cellular rejection bilirubin fell again but from then on it was maintained at a greater level. After discharge the patient experienced a further increase of bilirubin that returned to predischarge levels after readmission to the hospital. This was interpreted as poor compliance with phototherapy. Only partial correction of clinical jaundice and the poor tolerability to nocturnal phototherapy led the parents to refuse further hepatocyte infusions and request an orthotopic liver transplant. After 24 months the child is well, with good liver function on tacrolimus and prednisolone-based immunosuppression. Isolated AHT, though effective and safe, is not sufficient to correct CN1. Maintenance of adequate immunosuppression and family compliance are the main factors hampering the success of this procedure. 相似文献
80.
Villa E Fundarò P Moneta A Donatelli F 《The Annals of thoracic surgery》2005,79(2):752-752; author reply 753